ARIA: Vascular Manifestations of Amyloid Immunotherapy
New treatments could help curb the trend in Alzheimer’s patients. Presentation 9:15-10:45 a.m. in the Main Event Hall, Halls 1-3.
Data in recent years has shown an increasing trend in amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease being treated with amyloid-lowering monoclonal antibodies, such as lecanemab and donanemab. One of the leading researchers in this area is Stephen Salloway, MD, MS, founding director of the Memory and Aging Program (MAP) at Butler Hospital in Providence, Rhode Island, and professor of neurology and psychiatry at Warren Alpert Medical School of Brown University.
For more than 25 years, Dr. Salloway has conducted more than 125 clinical trials related to Alzheimer’s disease. At Butler Hospital’s MAP, he and his team have played a part in many major breakthroughs in Alzheimer’s diagnosis and treatment. His research has included studying ways to predict who is at risk for Alzheimer’s disease, developing approaches to prevent or slow its development through lifestyle modifications and identifying better diagnostic tests to promote early detection and treatment breakthroughs.
The MAP has helped pioneer the use of PET ligands for amyloid and tau to study the evolution of Alzheimer’s pathophysiology in autosomal dominant and sporadic Alzheimer’s disease. The program has played a lead role in testing treatments, such as monoclonal antibodies, to lower amyloid plaques and neurofibrillary tangles, as well as tested approaches, such as deep brain stimulation and antisense oligonucleotides, to slow the progression of Alzheimer’s.
